The identification of amylin+insulin- β-cells highlights the importance of using amylin cfDNA as an additional biomarker of β-cell death in RO T1D patients in conjunction with our previously reported insulin gene. This evidence concerns the gene IAPP and type 1 diabetes mellitus.